Pricing Log in Create free account

Gossamer Bio, Inc. (GOSS) vs Spero Therapeutics, Inc. (SPRO)

Gossamer Bio, Inc. and Spero Therapeutics, Inc. are both Biotechnology companies. Gossamer Bio, Inc. and Spero Therapeutics, Inc. are of similar size ($59.4M and $57.6M). Gossamer Bio, Inc. has negative trailing earnings, so its P/E is not meaningful; Spero Therapeutics, Inc. trades at 7.4×. Spero Therapeutics, Inc. grew revenue faster over the last twelve months: 37.2% against 32.4%. Spero Therapeutics, Inc. has the higher net margin (0.00% vs −235.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Spero Therapeutics, Inc. leads on 11 and Gossamer Bio, Inc. on 3.

Valuation

Metric GOSS SPRO Biotechnology median
P/E n/m 7.43 10.60
P/S 0.73 0.99 9.40
P/B n/m 1.36 2.13
Price to free cash flow n/m 3.09 25.18
EV/EBITDA n/m 1.58 0.66
EV/Sales 4.07 0.16 9.02
Earnings yield (467.69%) 13.46% (32.88%)
Free cash flow yield (417.17%) 32.41% (23.13%)

Profitability

Metric GOSS SPRO Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin (311.70%) 0.00% 0.00%
Net margin (235.00%) 0.00% 0.00%
Free cash flow margin (305.19%) 0.00% 0.00%
Return on equity 178.72% 19.17% (51.96%)
Return on assets (78.81%) 12.85% (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GOSS SPRO Biotechnology median
Revenue growth (TTM) 32.43% 37.24% 6.76%
EPS growth (last fiscal year) (200.00%) 111.81% 29.88%
Revenue growth, 5-year CAGR — 48.25% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GOSS SPRO Biotechnology median
Debt to equity (0.38) 0.00 0.00
Current ratio 0.53 6.12 4.97
Net debt to EBITDA (0.35) (6.38) 1.01

Dividend

Metric GOSS SPRO Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GOSS SPRO Biotechnology median
Market cap 57.56m 59.40m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack